Quintrio
Home

SERVICES-BUSINESS SERVICES, NEC

Claritev Corporation

CTEV

Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.

Last trade $22.31
Day change -$2.68 (-10.72%)
Day range $22.08 – $26.06
Volume 106,927
Market cap $427M

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$426.7M
Price / earnings
—
Price / book
-1.23×
Price / sales
0.42×
EV / sales
5.09×
EV / EBITDA
10.26×

Profitability

Earnings per share
-$16.11
Return on assets
-5.88%
Return on equity
79.38%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-13.75×
Current ratio
1.15×
Quick ratio
1.15×
Cash ratio
0.05×

Cash flow

Price / cash flow
3.25×
Price / free cash flow
—
Free cash flow
-$27.82M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CTEV, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$268.31M$257.48M$244.68M$246.55M$245.96M$241.57M$231.33M
Cost of revenue$69.77M$67.67M$69.08M$70.09M$62.06M$60.82M$60.44M
Gross profit$198.54M$189.81M$175.6M$176.46M$183.9M$180.75M$170.89M
Selling, general and administrative$66.33M$55.39M$57.83M$56.05M$60M$51.12M$46.97M
Research and development$0$0$0$0$0$0$0
Total operating expenses$177.8M$166.09M$168.92M$167.79M$171.94M$162.35M$157.49M
Operating income$20.73M$23.72M$6.68M$8.67M$11.96M$18.4M$13.41M
Interest expense-$100.9M-$100.25M-$99.54M-$99.41M-$101.23M-$99.75M-$91.64M
Income before taxes-$80.03M-$76.65M-$92.72M-$106.92M-$93.36M-$82.93M-$89.87M
Income taxes-$18.24M-$17.42M-$19.16M-$26.35M-$23.61M-$20.29M-$18.55M
Net income-$61.79M-$59.23M-$73.56M-$80.57M-$69.75M-$62.64M-$71.32M
Net income attributable to common shareholders-$61.78M-$59.23M-$73.56M-$80.57M-$69.75M-$62.64M-$71.32M
EBITDA$132.21M$134.42M$117.77M$120.41M$123.9M$129.63M$123.93M
Basic earnings per share-$3.64-$3.49-$4.41-$4.87-$4.23-$3.81-$4.38
Diluted earnings per share-$3.64-$3.49-$4.41-$4.87-$4.23-$3.81-$4.38

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Claritev Corporation (CTEV) Reports Q3 Loss, Tops Revenue Estimates

Claritev Corporation reported a quarterly loss of $3.64 per share, slightly beating consensus estimates of $3.68 loss, with revenues of $268.31 million exceeding expectations by 4.51%. However, the stock has underperformed significantly, down 46.9% year-to-date versus the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Claritev Corporation Reports Third Quarter 2026 Results

Claritev reported Q3 2026 revenues of $268.3 million, up 9.1% year-over-year, with Adjusted EBITDA of $162.0 million. Despite a net loss of $61.8 million, the company raised its full-year 2026 guidance and provided preliminary 2027 revenue expectations of $1.1 billion. The company highlighted growth across solutions and verticals, AI innovation initiatives, and new product launches including Transparency-Based Pricing.

Zacks Investment Research

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue Estimates

Fulgent Genetics reported a Q3 loss of $0.09 per share, significantly beating the consensus estimate of a $0.65 loss, representing an 86.15% earnings surprise. Revenue reached $90.41 million, surpassing estimates by 4.77%. However, the stock has underperformed the market by 25.1% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Omnicell (OMCL) Q3 Earnings and Revenues Top Estimates

Omnicell reported Q3 2026 earnings of $0.58 per share, beating consensus estimates of $0.42 by 38.10%, with revenues of $307.85 million slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 33.7% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Info Systems industry ranks in the top 38% of Zacks industries.

Zacks Investment Research

Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?

Tempus AI (TEM) shares gained 17.9% over the past month, outperforming peers like Claritev and iRhythm, driven by strong demand for healthcare AI. The company reported 28% revenue growth in its Data and Applications segment to $93.2M in Q2, with Insights revenues up 36%. However, TEM trades at a premium valuation of 6.59X sales versus the industry average of 4.70X, and its growth depends heavily on regulatory approvals and reimbursement decisions. Analysts recommend current holders maintain positions while prospective investors wait for a more favorable entry point.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.